Phase 1 data demonstrate activation of tumor-selectiveinterferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of action and the ongoing Phase 1 combination ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Merck & Co Inc. (NYSE:MRK) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 30, Merck & Co Inc.

The study will test the antibody-drug conjugate in combination with Keytruda in patients with HER2-overexpressing metastatic non-small cell lung cancer.

Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology ...

Phase 3 Trial Design: The FDA agreed with Adagene’s proposed standard-of-care (SOC) control arm for the Phase 3 clinical trial and confirmed that a muzastotug monotherapy arm was also not required.

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced a cost-cutting plan ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...